Europe Facial Injectable Market Size, Share & COVID-19 Impact Analysis, By Type (Botulinum Toxin, Collagen, Hyaluronic Acid, Calcium Hydroxylapatite, Polylactic Acid, Polymethyl-Methacrylate Microspheres (PMMA), Fat Injections, and Others), By Application (Wrinkle Reduction, Facelift, Acne Scar Treatment, Lipoatrophy Treatment, Lip Enhancement, and Others), By End-user (Hospitals & Ambulatory Surgery Centers, Dermatology and Cosmetic Clinics, and Others), and Regional Forecast, 2022-2029

The Europe facial injectable market size was valued at USD 2.20 billion in 2021. The market is projected to grow from USD 2.80 billion in 2022 to USD 3.70 billion by 2029, exhibiting a CAGR of 4.1% during the forecast period. The global COVID-19 pandemic has been unprecedented and staggering, with experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. Based on our analysis, the Europe facial injectable market exhibited a decline of 21.9% in 2020 as compared to 2019.

There has been a modification of attitudes toward cosmetic surgeries as many individuals are opting to enhance their aesthetic looks. This is owing to a strong increase in disposable income and rising awareness regarding aesthetic beauty across Europe. Several factors are responsible for the increase in adoption of these products due to the considerable safety that they offer and the little to no treatment and recovery time required in undertaking these minimally invasive procedures. These products include cosmetic neurotoxins such as botulinum toxin and dermal fillers such as hyaluronic acid and calcium hydroxylapatite.

Moreover, larger implementation of these products has led prominent companies in this market to increase their investments in various R&D activities for the development and introduction of novel products. For instance, in June 2021, Galderma announced that its product Alluzience had completed its European decentralized procedure, which resulted in a positive decision for the company’s first ready-to-use neuromodulator, a wrinkle relaxing injection, in Europe. Such developments by key companies are predicted to increase the procedural volume and ultimately boost the Europe facial injectable market growth during the forecast period.

COVID-19 IMPACT

Termination of Elective Processes Due to COVID-19 Caused Decline in Product Sales

Lockdowns imposed during the COVID-19 pandemic have caused a huge decline in the number of non-essential healthcare services such as cosmetic procedures to encourage safety concerns and to reduce the risk of infection across the region. According to an article by Derma Institute, in 2021, more than 81.0% of the aesthetic businesses in the U.K. had to close their clinics during the pandemic while 67.0% of revenues declined to reduce the risk of infection and the burden on the healthcare system. Such closures have negatively influenced the sales of these products in the Europe market due to substantial reduction in procedural volumes.

The pandemic has adversely impacted various companies’ supply chains, end-user demand for these products, and other commercialization activities. Key players in the market reported a decline in revenues of dermal fillers products in FY2020 as compared to the previous financial year of 2019. For example, in 2020, Allergan Aesthetics (AbbVie, Inc.), a strong player in the Europe market, recorded a decrease of 39.0% in the international market as compared to 2019 for the Juvederm Collection due to the closure of treatment centers and the cancellation of elective aesthetic procedures.

However, various specialty clinics and dermatological centers witnessed 70.0% increase in the requests for virtual consultations during the lockdown. Therefore, there will be strong market growth in FY2021 as restrictions have been eased and the postponed procedures have been performed due to the strong increase in pent-up demand. For instance, Revance Therapeutics, Inc. witnessed a 408.5% increase in 2021 revenue compared to 2020, which is primarily driven by the increase in the sales of products since the launch of the RHA dermal fillers collection in 2020. Furthermore, the surge in COVID-19 vaccinations is expected to sustain market growth for the foreseeable future.

LATEST TRENDS

Request a Free sample to learn more about this report.

Rising Acceptance of Facial Injectable Amongst Male Population to Drive Market Growth Prospects

One of the prevailing market trends in Europe market is that a surging percentage of the male demographic has demonstrated an interest in the adoption of these aesthetic products. There has been a boost in terms of consciousness in men, such as age that can deteriorate their facial appearances, which has led to an increase in demand for these cosmetic procedures. According to an article published by the Guardian in 2021, plastic surgeons in the U.K. have reported that the demand for injectable cosmetic procedures such as botulinum toxin by the male demographic has increased by 70.0%.

Furthermore, a robust proportion of the younger segment of the male demographic is opting for these products before their skin progresses an aged presence leading to the formation of wrinkles, which may be significantly delayed by adding volume and plumping up the skin. The usage of appropriate aesthetic products will decrease the likelihood of the development of new lines, creases, and folds or may also restore the plumpness of the lips. Hence, such trends are expected to significantly contribute to the growth of the Europe market during the forecast period.

DRIVING FACTORS

Increase in Demand for Aesthetic Cosmetic Operations to Fuel Growth in Europe

In Europe, the demand for cosmetic surgeries and minimally invasive or non-invasive cosmetic procedures, such as botulinum toxin and dermal filler injections, has increased tremendously over the past decade. Cosmetic procedures, which are invasive often require the patient to take certain additional days for recuperation from the surgical procedure. Hence, an increasing number of individuals are opting for minimally invasive procedures, which are painless and easier.

Moreover, the surge in demand for this type of cosmetic procedure has also led to a significant impact on the suppliers of dermatological preparations and other non-invasive technologies. They have engaged in new product launches to meet the demand for aesthetic procedures with improved patient outcomes. According to the International Society of Aesthetic Plastic Surgery (ISAPS) 2020 data, nonsurgical procedures performed in certain European countries were 1,157,738 in Germany, 830,868 in Italy, 397,512 in Spain, and 397,033 in Greece. Such sturdy growth developments in the practical volume are anticipated to strengthen the market growth.

Growth in Number of Practitioners Administering Facial Injectable to Determine Growth

In terms of procedural volumes, dermal filler ranks second amongst the top five nonsurgical cosmetic procedures behind botulinum toxin injections. An increasing number of dermal filler procedures due to surging in the popularity of dermal fillers to address the signs of aging, augmentation, and correction of lips and chin drives the market growth.

The market has the presence of more than 100 products of various material types, and dermal fillers are currently being used by several practitioners other than dermatologists and plastic surgeons. Cosmetic interventions are witnessing strong growth in terms of facial injectable procedures that can be performed by a number of healthcare practitioners such as General Practitioners (GP), consultant dermatologists, or plastic surgeons. According to the International Society of Aesthetic Plastic Surgery (ISAPS), Germany ranks second amongst the top 10 countries in the number of injectable procedures performed. Furthermore, Germany ranked 10th among the top 30 countries in the number of plastic surgeons. The increasing number of physicians and practitioners offering these procedures in the European countries would boost the market growth.

RESTRAINING FACTORS

High Cost and Comparative Side Effects of Facial Injectable to Hinder Market Growth

Aesthetic procedures offer various benefits; still, there are certain limiting factors that are restricting the market growth in the forecast period. One of the critical factors includes the high costs associated with these products, which vary based on the type of procedure coupled with the expertise and qualifications of the person performing the treatment, and the time & effort required to carry out the procedure or treatment. For instance, as per Med Beauty, hyaluronic acid fillers treatment in the U.K. with products such as the Juvederm Collection of hyaluronic acid derma ranges from USD 137.5 to USD 206.9, and the cost of a dermal filler treatment depends on the volume of dermal filler required. Furthermore, the requirement of repeated procedures of dermal fillers and botulinum toxin for the continued aesthetic effects is expected to contribute to the high costs of these procedures. This factor is anticipated to hinder the Europe market growth in the forecast period.

Another critical factor is the relative side effects caused by the administration of dermal fillers injections, which are rare but serious adverse reactions such as scarring, blurred vision, partial vision loss, and blindness if the facial injectable is inadvertently injected into a blood vessel are another major factor leading to the decline of the market growth.

SEGMENTATION

By Type Analysis

To know how our report can help streamline your business, Speak to Analyst

Wider Benefits Offered by Hyaluronic Acid to Lead Segment and Grow at the Highest CAGR 

Based on type, the Europe market can be segmented into botulinum toxin, collagen, hyaluronic acid, calcium hydroxylapatite, polylactic acid, PMMA, fat injections, and others.

The hyaluronic acid segment will dominate the market in 2021. The increase in demand for hyaluronic acid-based products is primarily driven by safety and the comparative longevity of these products. Furthermore, the presence of key companies offering hyaluronic acid facial injectable in Europe, such as Allergan Aesthetics (AbbVie, Inc.), is expected to drive the segment’s growth in the forecast period.

The second largest segment in 2021 was botulinum toxin, which was attributable to its significant procedural volume. Some beneficial aspects for this segment’s growth are the existence of key products such as Dysport from Galderma. Calcium hydroxylapatite accounted for the third-largest market share in the Europe market in 2021.

The polylactic acid segment is likely to grow with a significant CAGR over the forecast period due to latest advancements such as the re-launch of Sculptra in Europe. Robust demand for fat filler procedures across the region is predicted to contribute to the segment’s growth prospects during the forecast period. The PMMA and other segments are estimated to grow at a lower CAGR over the forecast period.

By Application Analysis

Wrinkle Reduction Occupies Dominating Share of Application Segment

In terms of application, the market is classified into wrinkle reduction, facelift, acne scar treatment, lipoatrophy treatment, lip enhancement, and others.

The wrinkle reduction segment dominated the market in 2021 and is expected to grow with the highest CAGR during the forecast period. The segment’s growth is accredited to the strong presence of prominent companies that address the needs of the patients and increase the awareness with respect to the effectiveness of these products for lines and wrinkles reduction.

The lip enhancement segment held the second-largest proportion of Europe facial injectable market share in 2021 and is expected to grow at a strong rate as the segment has a huge potential for growth in the Europe market. Some of the reasons for the segment’s growth include the robust demand for procedures such as lip augmentation, which is attracting the top companies to invest in new product launches. The third leading segment is projected to be the facelift segment, and its growth is attributed to the increase in beauty consciousness among women and the demand for products that rejuvenate damaged facial volume.

Other major application areas of the market are acne blemish treatment and lipoatrophy treatment. For the treatment of acne scars, Bellafill is the only U.S. FDA-approved dermal filler for this indication. The others segment is anticipated to grow at a lower CAGR during the forecast period.

By End-user Analysis

Dermatology and Cosmetic Clinics Segment to Exhibit Higher CAGR During 2022-2029

By end-user, the market is divided into hospitals & ambulatory surgery centers, dermatology and cosmetics clinics, and others.

The dermatology and cosmetic clinics generated the highest revenue, and the segment is expected to grow with a higher CAGR during the forecast period. Most of these procedures are carried out in dermatology and cosmetic clinics, and the rising prevalence of aesthetic problems, such as wrinkles and loss of facial volume, is expected to favor the expansion of the segment.

Hospitals & ambulatory centers are expected to grow at a significant CAGR during the forecast period. For example, various hospitals & ambulatory surgery centers in the U.K. offer these procedures to address a number of skin concerns, including the common signs of aging around the forehead and eyes, such as frown lines, laughter lines, and crow’s feet. The others segment is likely to grow at a lower CAGR during the forecast period.  

REGIONAL INSIGHTS

Strong Procedural Volume of Germany to Lead to Company’s Market Dominance

In terms of country/sub-region, the Europe market is studied across Germany, the Netherlands, the U.K., France, Italy, Belgium, Spain, Scandinavia, Greece, and the rest of Europe.

The Europe facial injectable market size stood at USD 2.20 billion in 2021, and the region is expected to observer stable growth trends during the forecast period. The robust volume of cosmetic processes, such as botulinum toxin and various dermal fillers across Europe, coupled with high expenditure on research & development activities by key companies in the market, is expected to drive the growth of the market in the forecast period.

In terms of country, Germany is predicted to account for the highest market size of USD 0.53 billion in 2021. Improved healthcare facilities, strong procedural volume, and a highly aware population are the key factors for the expansion of the market in this region. For instance, as per the ISAPS 2020 statistical data, the total number of non-surgical procedures performed involving injectable in Germany was 695,315.

France is expected to represent the second-highest market share in Europe during 2022-2029. The growth in France is likely to be propelled by the consistent increase in the number of injectable facial procedures, fresh product unveilings, strategic collaborations between major players, and active government support that are projected to further increase the demand and growth rate of these products in the country.

Italy held the third-largest market share in 2021 and is expected to reach a substantial market value during the forecast period, owing to the increase in the number of injectable procedures across the country. For example, as per the International Society of Aesthetic Plastic Surgery (ISAPS), in 2020, an estimated 240,264 procedures involving the hyaluronic acid dermal fillers were conducted, whereas 204,084 procedures were performed involving botulinum toxin injectable in Italy.

The U.K. is projected to witness a significant CAGR over the forecast period. The highly aware and economically stable population is driving the growth of the market across the country. Scandinavia and Spain will grow at lower CAGR, similar to the Netherlands and Belgium due to lesser volume of cosmetic procedures in these countries, coupled with limited expenditure on cosmetic procedures, including injectable fillers. Greece and the rest of Europe are anticipated to witness a relatively lower CAGR during the forecast period.

KEY INDUSTRY PLAYERS

Diverse Product Portfolio with Strategic Partnerships of Companies to Strengthen their Market Position

In the competitive landscape, Allergan Aesthetics (AbbVie) dominated the market due to its strong product portfolio with wide application areas in cosmetic procedures. The company’s aesthetics portfolio includes the hyaluronic acid-based dermal fillers range called the JUVEDERM Collection, which is indicated for a diverse range of cosmetic applications along with other prominent products such as the BOTOX Cosmetic, which collectively enables the corporation to maintain its domination during the forecast period.

Additional key companies in the market are Galderma and Merz Pharma due to their diverse product portfolio and strong distribution network in the global market. Galderma holds a significant market position due to its prominent product offering, such as the Restylane range of dermal fillers. Merz Pharma also holds a substantial share of the market with its products such as BELTERO, Xeomin, and Radiesse range of dermal fillers. Ipsen Pharma is another major player in the market with its product Dysport which has continued to perform well in the market. Other leading players include Revance Therapeutics, Inc., Teoxane, Sinclair Pharma, and others who are focusing on strategic collaborations and partnerships to expand their portfolio and increase their market share across the Europe dermal fillers market.

LIST OF KEY COMPANIES PROFILED:

• Allergan Aesthetics (AbbVie Inc.) (U.S.)


• Ipsen Pharma (France)


• Merz Pharma (Germany)


• Galderma (Switzerland)


• Revance Therapeutics, Inc. (U.S.)


• Sinclair Pharma (U.K.)


• BIOPLUS CO., LTD. (South Korea)


• Bioxis pharmaceuticals (France)


• Prollenium Medical Technologies (Canada)

KEY INDUSTRY DEVELOPMENTS:

• April 2022: Revance Therapeutics, Inc. received FDA acceptance of Biologics License Application (BLA) resubmission for DaxibotulinumtoxinA for the treatment of moderate to severe glabellar lines.


• March 2022: Allergan Aesthetics, an AbbVie company, launched HArmonyCa with lidocaine across Europe. It is a dual-effect hybrid injectable with two active ingredients, hyaluronic acid, and calcium hydroxyapatite.


• February 2022: Sinclair Pharma announced the acquisition of Viora. This acquisition helps the company expand its presence in the medical aesthetics devices market.


• December 2021: Allergan acquired announced the successful completion of its acquisition of Soliton, Inc. to complement Allergan Aesthetics' portfolio of non-invasive body contouring treatments to include a proven treatment for the appearance of cellulite.


• September 2021: Galderma and Sofregen announce an exclusive agreement to develop the next generation of biostimulator fillers using silk-based technology.

REPORT COVERAGE

An Infographic Representation of Europe Facial Injectable Market

View Full Infographic

To get information on various segments, share your queries with us

The Europe facial injectable market report provides detailed market analysis and focuses on key aspects such as the pricing analysis, key industry developments - mergers, partnerships, and acquisitions, new product launches, key industry trends, the impact of COVID-19 on the Europe market, proportion of facial type of injectables in total non-surgical procedures in EU5 countries, and insights related to specialists. Besides these, the report offers market forecast insights into opportunities and highlights key strategies by key players. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth of the market in recent years.

Report Scope & Segmentation